Will Dynavax’s (DVAX) Growth Momentum Continue in 2022? Posted byZacks Equity Research February 15, 2022 Leave a comment on Will Dynavax’s (DVAX) Growth Momentum Continue in 2022? Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022.